Healthy adults who were not suffering from any diseases (excluding those under 18, pregnant women, and lactating women)
Conditions
Interventions
None listed
Sponsors
FUJIFILM Corporation
Yakujihou Marketing Jimusho Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: A systematic literature search is performed through scientific and clinical trial registries databas Participants (P): Healthy adults who were not suffering from any diseases (excluding those under 18, pregnant women, and lactating women).?? Intervention (I): Intake of foods (tablets, capsules, granules, beverages, processed foods) containing astaxanthin. compositions that also contain ingredients other than Astaxanthin as test substances are excluded. Astaxanthin intake should be 0.4-30 mg/day.?? Comparison (C): The comparison group is set up as consuming a placebo food that does not contain Astaxanthin.?? Outcome(O): The primary outcome is inhibition of blood lipid oxidation , especially as an indicator of the oxidation state of blood lipids such as phospholipid hydroperoxide (PLOOH), malondialdehyde (MDA), and isoprostane (ISP)). Study design (S): Randomized, quasi-randomized, and non-randomized controlled trials (parallel group or crossover controlled trials) will be included.
Exclusion criteria
Exclusion criteria: Studies which do not meet the key inclusion criteria will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is inhibition of blood lipid oxidation, especially as an indicator of the oxidation state of blood lipids such as phospholipid hydroperoxide (PLOOH), malondialdehyde (MDA), and isoprostane (ISP)). | — |
Countries
Japan
Contacts
Public ContactHitomi Saito
FUJIFILM Corporation FUJIFILM Corporation
Outcome results
None listed